S11 Ep87: Midweek Takeaway featuring Jeremy Skillington and Cathal Friel from Poolbeg Pharma #POLB
This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001.
The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investment…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.